The FMC Board of Directors has approved divesting the company's commercial business in the country in response to challenges in India.

FMC plans to continue to actively participate in the India market through a supply agreement with the eventual buyer of the business for its patented and data-protected portfolio, ranging from new diamide technologies to active ingredients and biologicals. 

The company will continue its active ingredient manufacturing operations in India. The sale process is underway and is expected to conclude within the next year.

The India commercial business will be classified as held for sale beginning in the third quarter. Revenue generated by the India commercial business will be included in reported revenue, while revenue guidance for the company will exclude India